Market Overview

Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial

Alnylam
Pharmaceuticals, (NASDAQ: ALNY), a leading RNAi therapeutics
company, announced today the achievement of positive clinical results
from its Phase II trial of patisiran (ALN-TTR02), an RNAi therapeutic
targeting the transthyretin (TTR) gene for the treatment of TTR-mediated
amyloidosis (ATTR). The data
are being presented at the IXth International Symposium on Familial
Amyloidotic Polyneuropathy (ISFAP) being held in Rio de Janeiro, Brazil,
November 10 – 13. Results showed that multiple doses of patisiran led to
robust and statistically significant knockdown of serum TTR protein
levels of up to 96%, with mean levels of TTR knockdown exceeding 85%.
Knockdown of TTR, the disease-causing protein in ATTR, was found to be
rapid, dose dependent, and durable, and

See full press release

Posted-In: News Guidance Contracts FDA Management Global

 

Related Articles (ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters